Compare SNGX & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | TRIB |
|---|---|---|
| Founded | 1987 | 1992 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 14.0M |
| IPO Year | 2006 | 1996 |
| Metric | SNGX | TRIB |
|---|---|---|
| Price | $1.18 | $0.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 121.4K | ★ 159.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,371.00 | N/A |
| Revenue This Year | N/A | $13.51 |
| Revenue Next Year | N/A | $13.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $0.48 |
| 52 Week High | $6.23 | $3.44 |
| Indicator | SNGX | TRIB |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 46.66 |
| Support Level | $1.11 | $0.71 |
| Resistance Level | $1.22 | $0.80 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 76.11 | 61.84 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.